Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for autoimmune and chronic inflammatory diseases. Headquartered in San Francisco, California, the company utilizes its proprietary polymer conjugation technologies to create therapeutic candidates that modulate the immune system. Its lead product candidate, rezpegaldesleukin (REZPEG), is a regulatory T cell stimulator currently being evaluated in clinical trials for conditions such as atopic dermatitis and alopecia areata. The company's pipeline also includes preclinical programs targeting tumor necrosis factor receptors and modified hematopoietic colony-stimulating factors. Historically, Nektar has leveraged its PEGylation platform to partner with major pharmaceutical companies, enhancing the pharmacokinetics and therapeutic profiles of various biologics and small molecules.
